Equillium (EQ) Stock Price, News & Analysis

Company Overview

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Key Stats

• Today's Range: $0.58 to $0.61
• 50-Day Range: $0.60 to $1.38
• 52-Week Range: $0.56 to $3.25
• Volume: 108,772 shs
• Average Volume: 254,499 shs
• Market Capitalization: $21.54 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Buy

Equillium Stock Analysis - MarketRank™

Equillium scored higher than 58% of companies evaluated by MarketBeat, and ranked 449th out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Equillium has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Equillium has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Equillium are expected to decrease in the coming year, from ($0.12) to ($1.18) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Equillium is -4.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Equillium is -4.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Equillium has a P/B Ratio of 0.95. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.76% of the float of Equillium has been sold short.

Short Interest Ratio / Days to Cover

Equillium has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Equillium has recently decreased by 14.26%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Equillium does not currently pay a dividend.

Dividend Growth

Equillium does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.76% of the float of Equillium has been sold short.

Short Interest Ratio / Days to Cover

Equillium has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Equillium has recently decreased by 14.26%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

7 people have searched for EQ on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Equillium insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $38,248.00 in company stock.

Percentage Held by Insiders

30.30% of the stock of Equillium is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 27.05% of the stock of Equillium is held by institutions.

EQ Stock Analysis - Frequently Asked Questions

How have EQ shares performed this year?

Equillium's stock was trading at $0.7230 on January 1st, 2024. Since then, EQ shares have decreased by 15.9% and is now trading at $0.6080.
View the best growth stocks for 2024 here.

How were Equillium's earnings last quarter?

Equillium, Inc. (NASDAQ:EQ) released its earnings results on Wednesday, November, 10th. The company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by $0.01. Equillium had a negative trailing twelve-month return on equity of 20.68% and a negative net margin of 10.05%.

When did Equillium IPO?

Equillium (EQ) raised $70 million in an IPO on Friday, October 12th 2018. The company issued 4,700,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and Stifel served as the underwriters for the IPO.

How do I buy shares of Equillium?

Shares of EQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Equillium own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Equillium investors own include NVIDIA (NVDA), Meta Platforms (META), Bank of America (BAC), Advanced Micro Devices (AMD), AbbVie (ABBV), Tilray (TLRY) and Carnival Co. & (CCL).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EQ
• CUSIP: N/A
• CIK: 1746466
• Web: equilliumbio.com
• Phone: (858) 240-1200
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $5.00
• High Stock Price Target: $5.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +722.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.14)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-13,340,000.00
• Net Margins: -10.05%
• Pretax Margin: -10.02%
• Return on Equity: -20.68%
• Return on Assets: -10.77%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.04
• Quick Ratio: 3.04

Sales & Book Value

• Annual Sales: $45.91 million
• Price / Sales: 0.47
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.64 per share
• Price / Book: 0.95

Miscellaneous

• Outstanding Shares: 35,431,000
• Free Float: 24,695,000
• Market Cap: $21.54 million
• Optionable: Not Optionable
• Beta: 1.78